National Grid plc Stock Rating Reaffirmed by Morgan Stanley (NG.)

Share on StockTwits

National Grid plc (LON: NG.)‘s stock had its “overweight” rating reiterated by research analysts at Morgan Stanley in a report released on Monday, Stock Ratings Network.com reports. They currently have a GBX 880 ($13.36) target price on the stock.

A number of other firms have also recently commented on NG.. Analysts at JP Morgan Cazenove reiterated a “neutral” rating on shares of National Grid plc in a research note to investors on Friday. They now have a GBX 735 ($11.16) price target on the stock, down previously from GBX 785 ($11.92). Separately, analysts at RBC Capital reiterated an “outperform” rating on shares of National Grid plc in a research note to investors on Wednesday, May 29th. They now have a GBX 900 ($13.66) price target on the stock. Finally, analysts at BNP Paribas downgraded shares of National Grid plc from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, May 21st. They now have a GBX 780 ($11.84) price target on the stock.

Three analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 755.78 ($11.47).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Walmart Cuts Workers Hours After Making Pay Raises
Walmart Cuts Workers Hours After Making Pay Raises
Pentagon Teaming Up with Boeing and Apple for Wearable Tech
Pentagon Teaming Up with Boeing and Apple for Wearable Tech
One-Hour Delivery by Amazon Arrives in Seattle
One-Hour Delivery by Amazon Arrives in Seattle
Dangerous Bacteria in Ground Beef Shows Study
Dangerous Bacteria in Ground Beef Shows Study
Vital Therapies Stock Plunges Following Failed Trial For Liver Therapy
Vital Therapies Stock Plunges Following Failed Trial For Liver Therapy
Sears Reports Profit for the Quarter But Sales Drop
Sears Reports Profit for the Quarter But Sales Drop


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.